Luna Announces $2.1 Million Grant for BioDefense Agent
18 Junho 2008 - 9:53AM
Business Wire
Luna Innovations Incorporated (NASDAQ:LUNA) has been awarded a $2.1
million three-year contract from the National Institutes of Health
(NIH) to develop a novel therapeutic for infectious diseases.
Bacterial, viral and parasitic intracellular pathogens, organisms
that sustain infection by living inside a person's cells, use the
cell�s signaling pathways to establish and maintain infection. Luna
has previously demonstrated that a protein involved in cell-to-cell
communication called ribosomal S6 kinase (RSK), is critical for
intracellular pathogens to maintain infection. For this program,
Luna will advance a new class of anti-infective therapeutics, based
upon RSK inhibition, to interfere with the ability of the pathogen
to establish infection and survive inside the host organism.
Anti-infective therapeutics are especially critical due to the
potential to weaponize intracellular pathogens as an agent of
biowarfare. �The significance of the RSK pathway and the first RSK
inhibitor compounds were initially discovered by scientists at the
University of Virginia (UVA). This new program gives us the
opportunity to advance our RSK inhibitor technology to the next
level and address critical preclinical milestones,� said Kent
Murphy, Chairman and CEO of Luna Innovations. �Luna exclusively
licensed the technology and has worked closely with UVA and other
collaborators to better understand the RSK pathway and develop
novel RSK inhibitors. In addition to the treatment of infectious
diseases, the RSK pathway and novel RSK inhibitors have shown early
promise for treatment of other conditions such as cancer and
arthritis,� said Jeff Smith, Senior Research Scientist and
Principal Investigator on this program. About Luna Innovations:
Luna Innovations Incorporated (www.lunainnovations.com) develops
and manufactures new-generation products for the healthcare,
telecommunications, energy and defense markets. Our products are
used to measure, monitor, protect and improve critical processes in
the markets we serve. Through its disciplined commercialization
business model, Luna has become a recognized leader in
transitioning science to solutions. Luna is headquartered in
Roanoke, Virginia. Forward Looking Statements: This release
includes information that constitutes �forward-looking statements�
made pursuant to the safe harbor provision of the Private
Securities Litigation Reform Act of 1995, including statements
regarding, but not limited to: Luna�s ability to advance a new
class of anti-infective therapeutics, based upon RSK inhibition,
Luna�s ability to advance the RSK inhibitor technology including by
meeting preclinical milestones, the promise of the RSK pathway and
RSK inhibitors to treat medical conditions, including cancer and
arthritis. Statements that describe the Company�s business
strategy, goals, prospects, opportunities, outlook, plans or
intentions are also forward looking statements. Actual results may
differ materially from the expectations expressed in such
forward-looking statements as a result of various factors,
including risks and uncertainties set forth in the company�s
periodic reports and other filings with the Securities and Exchange
Commission. Such filings are available at the SEC�s website at
http://www.sec.gov, and at the company�s website at
http://www.lunainnovations.com. The statements made in this release
are based on information available to the company as of the date of
this release and Luna Innovations undertakes no obligation to
update any of the forward-looking statements after the date of this
release.
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024